Trial Profile
Phase I-II study of ZD1839 (Iressa) [gefitinib], cisplatin, and external-beam radiation therapy in patients with locally advanced, non-metastatic, squamous cell carcinoma of the head and neck
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 24 Aug 2007
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Cisplatin
- Indications Head and neck cancer
- Focus Adverse reactions; Therapeutic Use
- 19 Jul 2007 Status changed from recruiting to discontinued.
- 27 Oct 2005 New trial record.